Research & Literature

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Cigognetti M, Lonardi S, Fisogni S, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(8)):1043-57 doi:10.1038/modpathol.2015.65.

Malignant Mesothelioma Diagnosis.

Arif Q, Husain AN

Archives of pathology & laboratory medicine 2015; (139(8)):978-80 doi:10.5858/arpa.2013-0381-RA.

Biomarkers and prognostic factors for malignant pleural mesothelioma.

Vigneri P, Martorana F, Manzella L, Stella S

Future oncology (London, England) 2015; (11(24 Suppl)):29-33 doi:10.2217/fon.15.317.

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.

Billé A, Krug LM, Woo KM, et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016; (11(2)):249-55.

Comments on the causation of malignant mesothelioma: Rebutting the false concept that recent exposures to asbestos do not contribute to causation of mesothelioma.

Terracini B, Mirabelli D, Baur X, et al.

American journal of industrial medicine 2016; (59(6)):506-7 doi:10.1002/ajim.22590.

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.

Rimner A, Zauderer MG, Gomez DR, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(23)):2761-8 doi:10.1200/JCO.2016.67.2675.

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.

Bibby AC, Tsim S, Kanellakis N, et al.

European respiratory review : an official journal of the European Respiratory Society 2016; (25(142)):472-486 doi:10.1183/16000617.0063-2016.

The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database.

Wang S, Ma K, Wang Q, et al.

International journal of surgery (London, England) 2017; (48()):92-98 doi:10.1016/j.ijsu.2017.10.034.

A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.

Kinoshita Y, Hida T, Hamasaki M, et al.

Cancer cytopathology 2018; (126(1)):54-63 doi:10.1002/cncy.21928.

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Kindler HL, Ismaila N, Armato SG, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(13)):1343-1373 doi:10.1200/JCO.2017.76.6394.

Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.

Berg KB, Dacic S, Miller C, et al.

Archives of pathology & laboratory medicine 2018; (142(12)):1549-1553 doi:10.5858/arpa.2018-0273-OA.

Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma.

van Gerwen M, Wolf A, Liu B, et al.

Journal of surgical oncology 2018; (118(7)):1178-1187 doi:10.1002/jso.25260.

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al.

The Lancet. Respiratory medicine 2019; (7(3)):260-270 doi:10.1016/S2213-2600(18)30420-X.

Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.

Le Stang N, Burke L, Blaizot G, et al.

Archives of pathology & laboratory medicine 2020; (144(4)):446-456 doi:10.5858/arpa.2018-0457-OA.

Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.

Chapel DB, Schulte JJ, Husain AN, Krausz T

Translational lung cancer research 2020; (9(Suppl 1)):S3-S27 doi:10.21037/tlcr.2019.11.29.

Mediastinal undifferentiated pleomorphic sarcoma with pleural effusion cytopathologically misdiagnosed as epithelial malignant pleural mesothelioma: An autopsy case report.

Matsumoto K, Nakamura Y, Inagaki Y, et al.

Thoracic cancer 2021; (12(7)):1137-1140 doi:10.1111/1759-7714.13898.

Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.

Louw A, Lee YCG, Acott N, et al.

Cytopathology : official journal of the British Society for Clinical Cytology 2022; (33(1)):84-92 doi:10.1111/cyt.13015.

Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.

Savic I, Myers J

Acta medica academica 2021; (50(1)):197-208 doi:10.5644/ama2006-124.335.

Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.

Terra S, Roden AC, Yi ES, et al.

American journal of clinical pathology 2022; (157(1)):33-39 doi:10.1093/ajcp/aqab091.

Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology.

Girolami I, Lucenteforte E, Eccher A, et al.

Cancer cytopathology 2022; (130(2)):96-109 doi:10.1002/cncy.22509.

Malignant pleural mesothelioma patients' experience by gender: findings from a cross-sectional UK-national questionnaire.

Senek M, Robertson S, Darlison L, et al.

BMJ open respiratory research 2022; (9(1)) doi:10.1136/bmjresp-2021-001050.

The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma.

Wheatley-Price P, Moore S, Lee CW

JTO clinical and research reports 2022; (3(4)):100300 doi:10.1016/j.jtocrr.2022.100300.

Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma.

Strange CD, Marom EM, Ahuja J, et al.

Advances in anatomic pathology 2023; (30(4)):280-291 doi:10.1097/PAP.0000000000000386.

Small RNA-Seq Transcriptome Profiling of Mesothelial and Mesothelioma Cell Lines Revealed microRNA Dysregulation after Exposure to Asbestos-like Fibers.

Filetti V, Lombardo C, Loreto C, et al.

Biomedicines 2023; (11(2)) doi:10.3390/biomedicines11020538.

Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma.

Ebinç S, Oruç Z, Kalkan Z, et al.

Turk gogus kalp damar cerrahisi dergisi 2023; (31(1)):105-115 doi:10.5606/tgkdc.dergisi.2023.23365.

New developments in mesothelial pathology.

Churg A

Histopathology 2024; (84(1)):136-152 doi:10.1111/his.15007.

Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy.

Cedres S, Valdivia A, Iranzo P, et al.

Cancers 2023; (15(24)) doi:10.3390/cancers15245787.

Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort.

Conway RJH, Smith N, Cooper W, et al.

ERJ open research 2023; (9(6)) doi:10.1183/23120541.00467-2023.

Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.

Parra-Medina R, Castañeda-González JP, Chaves-Cabezas V, et al.

Pathology, research and practice 2024; (257()):155276 doi:10.1016/j.prp.2024.155276.

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.

Lim E, Waller D, Lau K, et al.

The Lancet. Respiratory medicine 2024; (12(6)):457-466 doi:10.1016/S2213-2600(24)00119-X.

Malignant pleural mesothelioma: The disdained member of thoracic oncology!

Khosla D, Singh PK, Chhabria BA, et al.

World journal of experimental medicine 2024; (14(3)):91739 doi:10.5493/wjem.v14.i3.91739.

Treatment of Pleural Mesothelioma: ASCO Guideline Update.

Kindler HL, Ismaila N, Bazhenova L, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(8)):1006-1038 doi:10.1200/JCO-24-02425.

Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma.

Lucà S, Pignata G, Cioce A, et al.

Cancers 2025; (17(3)) doi:10.3390/cancers17030481.

Malignant pleural mesothelioma.

Rao D P, Vijayan S, Vananjakar SS, T PK

BMJ case reports 2025; (18(2)) doi:10.1136/bcr-2024-263562.

Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score.

Guijosa A, Cabrera-Miranda LA, Gómez-García AP, et al.

Oncology 2025; (103(12)):1088-1096 doi:10.1159/000543637.

Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status.

Orozco-Castaño C, Mejía-Garcia A, Tsao HM, et al.

Journal of the Egyptian National Cancer Institute 2025; (37(1)):25 doi:10.1186/s43046-025-00284-0.

The usefulness of full-thickness biopsy during semi-rigid pleuroscopy for differentiating between malignant pleural mesothelioma and non-specific pleurisy.

Ueda T, Nakai T, Tanaka S, et al.

BMC pulmonary medicine 2025; (25(1)):553 doi:10.1186/s12890-025-03982-6.

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Scherpereel A, Baas P, Nowak AK, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; (44(9)):742-749 doi:10.1200/JCO-25-01328.

Diagnosis and management of pleural mesothelioma: three unique cases and review of the literature.

Al Achkar Z, Gaspard D, Iskandar M

BMC pulmonary medicine 2026; (26(1)).

Clinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings.

Thabit DM, Thabet DM

Journal of clinical pathology 2026; (79(7)):475-485 doi:10.1136/jcp-2026-210673.